MCID: SQM006
MIFTS: 59

Squamous Cell Carcinoma

Categories: Rare diseases, Cancer diseases, Skin diseases

Aliases & Classifications for Squamous Cell Carcinoma

MalaCards integrated aliases for Squamous Cell Carcinoma:

Name: Squamous Cell Carcinoma 12 76 53 37 29 6 15 73
Epidermoid Carcinoma 12 76 53
Squamous Cell Carcinoma of the Skin 29 6
Carcinoma, Squamous Cell 76 53
Squamous Cell Cancer 12 55
Squamous Cell Carcinoma - Category 73
Malignant Squamous Cell Neoplasm 73
Squamous Cell Carcinoma of Skin 73
Malignant Squamous Cell Tumor 12
Squamous Cell Epithelioma 12
Squamous Cell Skin Cancer 53
Neoplasms, Squamous Cell 44
Carcinoma Squamous Cell 55
Squamous Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1749
NCIt 50 C2929
KEGG 37 H00040

Summaries for Squamous Cell Carcinoma

NIH Rare Diseases : 53 Squamous cell carcinoma (SCC) is the second most common skin cancer. SCC most often affects individuals who are exposed to large amounts of sunlight. It is typically characterized by a red papule or plaque with a scaly or crusted surface; it may be suspected whenever a small, firm reddish-colored skin lesion, growth or bump appears on the skin, but it may also be a flat growth with a curly and crusted surface. Most often these growths are located on the face, ears, neck, hands and/or arms, but they may occur on the lips, mouth, tongue, genitalia or other area. The most common causes of SCC are radiation from the sun and arsenic exposure. With appropriate treatment, it is usually curable.

MalaCards based summary : Squamous Cell Carcinoma, also known as epidermoid carcinoma, is related to skin squamous cell carcinoma and squamous cell carcinoma, head and neck. An important gene associated with Squamous Cell Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Glioblastoma Multiforme and Senescence and Autophagy in Cancer. The drugs Erbitux and Intron A have been mentioned in the context of this disorder. Affiliated tissues include lung, skin and tongue.

Disease Ontology : 12 A carcinoma that derives from squamous epithelial cells.

Wikipedia : 76 Squamous cell carcinomas, also known as epidermoid carcinoma are a number of different types of cancer... more...

Related Diseases for Squamous Cell Carcinoma

Diseases related to Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 777)
# Related Disease Score Top Affiliating Genes
1 skin squamous cell carcinoma 35.4 BRAF HRAS TP53
2 squamous cell carcinoma, head and neck 35.0 BRAF C5orf66-AS1 H19 HOTAIR HRAS MIR205
3 tongue squamous cell carcinoma 34.9 LINC01503 MALAT1 TP53 UCA1
4 vulva squamous cell carcinoma 34.8 MALAT1 TP53
5 esophagus squamous cell carcinoma 34.7 HOTAIR LINC01233 TUG1
6 lung squamous cell carcinoma 34.7 BRAF CCAT2 HRAS SOX2-OT TP53 TUG1
7 oral squamous cell carcinoma 34.5 CCAT2 H19 HOTAIR MALAT1 TUG1 UCA1
8 nasopharyngeal carcinoma 34.0 CASC9 H19 HOTAIR HRAS MALAT1 TP53
9 adenocarcinoma 33.9 BRAF H19 HRAS TP53
10 esophageal cancer 33.7 C5orf66-AS1 CASC9 H19 HOTAIR HRAS MALAT1
11 prostate cancer 32.0 CCAT2 H19 HOTAIR HRAS MALAT1 MIR205
12 sarcoma 32.0 BRAF HOTAIR HRAS TP53
13 suppression of tumorigenicity 12 31.8 BRAF HRAS TP53
14 bladder cancer 31.8 C5orf66-AS1 CCAT2 H19 HOTAIR HRAS MALAT1
15 gastric adenocarcinoma 31.8 BRAF H19 HOTAIR HRAS TP53
16 lung cancer 31.7 BRAF CASC9 CCAT2 DDR2 H19 HOTAIR
17 lung cancer susceptibility 3 31.7 BRAF H19 HOTAIR HRAS MALAT1 TP53
18 colorectal adenocarcinoma 31.6 BRAF HRAS TP53
19 thyroid cancer, nonmedullary, 1 31.5 BRAF H19 HOTAIR MALAT1
20 small cell cancer of the lung 31.5 CCAT2 HOTAIR MALAT1 TP53 TUG1
21 skin melanoma 31.4 BRAF HRAS TP53
22 gastric cardia adenocarcinoma 31.4 C5orf66-AS1 H19 HOTAIR
23 lip cancer 31.2 BRAF TP53
24 melanoma 31.1 BRAF H19 HOTAIR MALAT1 MIR205 SOX2-OT
25 adrenocortical carcinoma, hereditary 31.0 BRAF H19 TP53
26 cervical cancer 31.0 CCAT2 H19 HOTAIR HRAS MALAT1 SPRY4-IT1
27 mature teratoma 30.9 BRAF TP53
28 thyroid cancer 30.8 BRAF H19 HOTAIR HRAS MALAT1 TP53
29 intrahepatic cholangiocarcinoma 30.8 CCAT2 TP53 TUG1
30 b-cell lymphomas 30.8 HOTAIR MALAT1 TP53 TUG1
31 leukemia, chronic myeloid 30.7 H19 HOTAIR HRAS UCA1
32 renal cell carcinoma, nonpapillary 30.5 H19 HOTAIR MALAT1 TUG1 UCA1
33 myeloma, multiple 30.4 BRAF H19 HOTAIR HRAS MALAT1 TP53
34 glioma 30.3 BRAF CCAT2 H19 HOTAIR MALAT1 SPRY4-IT1
35 cholangiocarcinoma 29.9 CCAT2 H19 HRAS MALAT1 SOX2-OT SPRY4-IT1
36 hepatocellular carcinoma 29.9 CCAT2 H19 HOTAIR HRAS MALAT1 MIR205
37 osteogenic sarcoma 29.7 CCAT2 H19 HOTAIR MALAT1 SOX2-OT TP53
38 colorectal cancer 29.7 BRAF CCAT2 H19 HOTAIR HRAS MALAT1
39 breast cancer 29.7 BRAF CCAT2 H19 HOTAIR HRAS MALAT1
40 gastric cancer 29.6 CASC9 CCAT2 H19 HOTAIR MALAT1 RIOX2
41 basaloid squamous cell carcinoma 12.4
42 conjunctival squamous cell carcinoma 12.4
43 adenoid squamous cell carcinoma 12.4
44 keratinizing squamous cell carcinoma 12.4
45 palmoplantar hyperkeratosis with squamous cell carcinoma of skin and 46,xx sex reversal 12.4
46 cervical squamous cell carcinoma 12.4
47 gastric squamous cell carcinoma 12.3
48 breast squamous cell carcinoma 12.3
49 penis squamous cell carcinoma 12.3
50 rectum squamous cell carcinoma 12.3

Graphical network of the top 20 diseases related to Squamous Cell Carcinoma:



Diseases related to Squamous Cell Carcinoma

Symptoms & Phenotypes for Squamous Cell Carcinoma

Drugs & Therapeutics for Squamous Cell Carcinoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Erbitux 18 49 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
2
Intron A 18 49 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
3
Taxotere 18 49 DOCETAXEL Rhone Poulenc Rorer May 1996

Drugs for Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 579)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 15663-27-1 84093 441203 2767
2
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 114977-28-5 148124
3
Cetuximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 205923-56-4 56842117 2333
4
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-21-8 3385
5
Ethanol Approved Phase 4,Phase 1,Not Applicable 64-17-5 702
6
Petrolatum Approved, Investigational Phase 4 8009-03-8
7 Titanium dioxide Approved Phase 4 13463-67-7
8
Imiquimod Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 99011-02-6 57469
9
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 41575-94-4 10339178 498142 38904
10
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 184475-35-2 123631
11
Pemetrexed Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 150399-23-8, 137281-23-3 446556 60843
12
Nedaplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 95734-82-0
13
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 154361-50-9 60953
14
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
15
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33069-62-4 36314
16
Raltitrexed Approved, Investigational Phase 4,Phase 3 112887-68-0 104758
17
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
18
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
19
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
20
Cevimeline Approved Phase 4,Phase 3 107233-08-9 83898 25137844
21
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 60-00-4, 62-33-9 6049
22
Pentetic acid Approved Phase 4,Phase 3,Phase 2 67-43-6
23
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
24
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
25
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
26
Tacrolimus Approved, Investigational Phase 4,Phase 3 104987-11-3 445643 439492
27
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 437-38-7 3345
28
Acitretin Approved Phase 4,Phase 2,Not Applicable 55079-83-9 6437841 5284513
29
Morphine Approved, Investigational Phase 4 57-27-2 5288826
30
Azathioprine Approved Phase 4 446-86-6 2265
31
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
32
Mycophenolic acid Approved Phase 4 24280-93-1 446541
33
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
34
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
35
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 11103-57-4, 68-26-8 445354
36
Camptothecin Experimental Phase 4,Phase 3,Phase 2,Phase 1 7689-03-4
37 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
38 Endostatins Phase 4,Phase 3,Phase 2,Phase 1 71581480
39 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Mitomycins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Anti-Allergic Agents Phase 4,Phase 2
48 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 mometasone furoate Phase 4

Interventional clinical trials:

(show top 50) (show all 2099)
# Name Status NCT ID Phase Drugs
1 Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma Unknown status NCT02513342 Phase 4 Docetaxel;Cisplatin
2 Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Unknown status NCT02015650 Phase 4 Cetuximab;Mitomycin-C/ 5-Fluorouracil
3 Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Unknown status NCT02495064 Phase 4 Mometasone Furoate Cream
4 A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma Unknown status NCT00642239 Phase 4 placebo;Sodium Glycididazole
5 Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE) Unknown status NCT01553032 Phase 4 Erbitux®
6 Stereotactic Body Radiotherapy for Head and Neck Tumors Unknown status NCT01344356 Phase 4
7 Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses Unknown status NCT01229319 Phase 4 Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm;Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
8 Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
9 Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma Completed NCT02088515 Phase 4 Nedaplatin;Cisplatin;Docetaxel
10 Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip Completed NCT00868088 Phase 4
11 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial Completed NCT00847912 Phase 4 5-fluorouracil;Placebo, vehicle control
12 Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2) Completed NCT01453179 Phase 4 Imiquimod;Diclofenac
13 Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx Carcinoma Completed NCT00772681 Phase 4 docetaxel and cisplatin
14 An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck Completed NCT00684385 Phase 4 ZD1839
15 Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced Xerostomia Completed NCT00466388 Phase 4 Cevimeline
16 Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours Completed NCT00220168 Phase 4 Irinotecan, Capecitabine
17 Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Head & Neck Cancer Patients Completed NCT02622880 Phase 4
18 Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer Completed NCT02287675 Phase 4 Lymphoseek;Sulfur Colloid
19 Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients Completed NCT00129961 Phase 4 sirolimus;cyclosporine or tacrolimus
20 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
21 Post-Operative Drainage Following Lymph Node Dissection Completed NCT00324272 Phase 4 Fibrin Sealant (Tisseel) used in the Experimental Arm.
22 Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Completed NCT00046969 Phase 4 cisplatin
23 A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer Patients Completed NCT01283906 Phase 4
24 Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome Completed NCT00266656 Phase 4 Humatrope
25 Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With HNSCC. Recruiting NCT03196843 Phase 4 Raltitrexed
26 Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy Recruiting NCT02869321 Phase 4 Fentanyl;Morphine Sulfate;Fentanyl placebo;Morphine Sulfate placebo
27 Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5% Active, not recruiting NCT01926496 Phase 4 Ingenol Mebutate Gel, 0.015%;Imiquimod Cream, 5%
28 Lipusu Advanced Squamous Cell Carcinoma of Lung Study Carboplatin in Advanced Squamous Cell Carcinoma of Lung Not yet recruiting NCT02996214 Phase 4 Paclitaxel Liposome;Gemcitabine;Cisplatin
29 Acitretin Plasma Levels Under Hemodialysis Suspended NCT00488384 Phase 4 Chemopreventive application (Acitretin)
30 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT00866684 Phase 4 Sirolimus;Azathioprine;Mycophenolate;Ciclosporin;Tacrolimus
31 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4 Sirolimus
32 Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV Withdrawn NCT01663558 Phase 4 imiquimod
33 Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy Unknown status NCT01402180 Phase 2, Phase 3 chemotherapy;chemotherapy
34 Chemoprevention of Esophageal Squamous Cell Carcinoma (ESCC) With Aspirin and Tea Polyphenols Unknown status NCT01496521 Phase 3 Aspirin
35 Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer Unknown status NCT02485548 Phase 3 Raltitrexed;5-fluorouracil;Cisplatin
36 Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma Unknown status NCT01752205 Phase 3 Paclitaxel;Erlotinib
37 Is ENI Necessary For Patients With Thoracic Esophageal Cancer After Esophagectomy And With Pathological Stage Of T1-2,N+,M0 Unknown status NCT01398449 Phase 3
38 E10A for the Treatment of Squamous Cell Carcinoma of the Head and Neck Unknown status NCT02630264 Phase 3 Endostatins;Paclitaxel injection;Cisplatin injection
39 Oral Cancer Adjuvant Therapy (OCAT) Trial Unknown status NCT00193843 Phase 3
40 Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth Cancer Unknown status NCT00002747 Phase 3 cisplatin;fluorouracil
41 Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment Unknown status NCT00935675 Phase 3 Escitalopram
42 Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma Unknown status NCT01947062 Phase 3 Intravenous Cisplatin & etoposide;Intravenous Cisplatin & etoposide along with oral cyclophosphamide
43 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
44 S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer Unknown status NCT00336947 Phase 3 tegafur-gimeracil-oteracil potassium;tegafur-uracil
45 Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx Unknown status NCT00002702 Phase 3
46 Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Advanced Cancer of the Oropharynx or Hypopharynx Unknown status NCT00003627 Phase 3 cisplatin;fluorouracil
47 Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate Unknown status NCT00041613 Phase 3
48 Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone Unknown status NCT00041626 Phase 3
49 Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial Unknown status NCT02319187 Phase 3 S1;S-1;irinotecan
50 Evaluation of 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Cancer. Unknown status NCT01124409 Phase 3

Search NIH Clinical Center for Squamous Cell Carcinoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: neoplasms, squamous cell

Genetic Tests for Squamous Cell Carcinoma

Genetic tests related to Squamous Cell Carcinoma:

# Genetic test Affiliating Genes
1 Squamous Cell Carcinoma 29
2 Squamous Cell Carcinoma of the Skin 29

Anatomical Context for Squamous Cell Carcinoma

MalaCards organs/tissues related to Squamous Cell Carcinoma:

41
Lung, Skin, Tongue, Lymph Node, Cervix, Endothelial, T Cells

Publications for Squamous Cell Carcinoma

Articles related to Squamous Cell Carcinoma:

(show top 50) (show all 13102)
# Title Authors Year
1
XBP1 promotes tumor invasion and is associated with poor prognosis in oral squamous cell carcinoma. ( 29916547 )
2018
2
Curcumin enhances anti-tumor immune response in tongue squamous cell carcinoma. ( 29751146 )
2018
3
Squamous Cell Carcinoma of the Gingiva Mimicking Periodontal Disease: A Diagnostic Challenge and Therapeutic Dilemma. ( 29447319 )
2018
4
The Positive Relationship Between I^H2AX and PD-L1 Expression in Lung Squamous Cell Carcinoma. ( 29275316 )
2018
5
Propofol improves the function of natural killer cells from the peripheral blood of patients with esophageal squamous cell carcinoma. ( 29977357 )
2018
6
Airway brushing as a new experimental methodology to detect airway gene expression signatures in mouse lung squamous cell carcinoma. ( 29891994 )
2018
7
Serum bilirubin level predicts post-operative overall survival in oral squamous cell carcinoma. ( 29430757 )
2018
8
CXCL1 induces senescence of cancer-associated fibroblasts via autocrine loops in oral squamous cell carcinoma. ( 29360827 )
2018
9
NIPA-like domain containing 1 is a novel tumor-promoting factor in oral squamous cell carcinoma. ( 29464350 )
2018
10
FNDC3B promotes epithelial-mesenchymal transition in tongue squamous cell carcinoma cells in a hypoxic microenvironment. ( 29393475 )
2018
11
Reply to 'Comment on 'Prognostic biomarkers for oral tongue squamous cell carcinoma: a systematic review and meta-analysis". ( 29449674 )
2018
12
Association of Retinoic Acid Receptor I^ Gene With Onset and Progression of Lichen Sclerosus-Associated Vulvar Squamous Cell Carcinoma. ( 29898214 )
2018
13
Degenerated Keratinized Tumor Cells in Oropharyngeal Human Papilloma Virus-Associated Squamous Cell Carcinoma: A Pitfall in p16 Immunostaining of Fine-Needle Aspiration Specimens. ( 29966127 )
2018
14
Tumor spread through air spaces is a useful predictor of recurrence and prognosis in stage I lung squamous cell carcinoma, but not in stage II and III. ( 29748009 )
2018
15
TGF-I^1/TI^RII/Smad3 signaling pathway promotes VEGF expression in oral squamous cell carcinoma tumor-associated macrophages. ( 29462614 )
2018
16
Nimotuzumab combined with chemotherapy as first-line treatment for advanced lung squamous cell carcinoma. ( 29920955 )
2018
17
Expression of Sphingosine Kinase-1 Is Associated with Invasiveness and Poor Prognosis of Oral Squamous Cell Carcinoma. ( 29491060 )
2018
18
Non-invasive imaging of actinic cheilitis and squamous cell carcinoma of the lip. ( 29725529 )
2018
19
Canonical Wnt pathway gene expression and their clinical correlation in oral squamous cell carcinoma. ( 29900911 )
2018
20
Expression of CD44, CD44v9, ABCG2, CD24, Bmi-1 and ALDH1 in stage I and II oral squamous cell carcinoma and their association with clinicopathological factors. ( 29963189 )
2018
21
The long non-coding RNA AK001796 contributes to tumor growth via regulating expression of p53 in esophageal squamous cell carcinoma. ( 29568233 )
2018
22
Gadd45a gene silencing by RNAi promotes cell proliferation and inhibits apoptosis and senescence in skin squamous cell carcinoma through the p53 signaling pathway. ( 29663367 )
2018
23
Comment on 'Prognostic biomarkers for oral tongue squamous cell carcinoma: a systematic review and meta-analysis'. ( 29449675 )
2018
24
Multiple roles of single-minded 2 in esophageal squamous cell carcinoma and its clinical implications. ( 29427302 )
2018
25
Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma. ( 29939876 )
2018
26
A rapidly growing human papillomavirus-positive oral tongue squamous cell carcinoma in a 21-year old female: A case report. ( 29849799 )
2018
27
Expression and oncogenic properties of membranous Notch1 in oral leukoplakia and oral squamous cell carcinoma. ( 29620248 )
2018
28
Correction: Morphoproteomic Characterization of Lung Squamous Cell Carcinoma Fragmentation, a Histological Marker of Increased Tumor Invasiveness. ( 29437123 )
2018
29
miR-409-3p suppresses the proliferation, invasion and migration of tongue squamous cell carcinoma via targeting <i>RDX</i>. ( 29928443 )
2018
30
Targeting sphingosine kinase 2 by ABC294640 inhibits human skin squamous cell carcinoma cell growth. ( 29428730 )
2018
31
Extracellular interleukin-17F has a protective effect in oral tongue squamous cell carcinoma. ( 29761594 )
2018
32
Squamous Cell Carcinoma and Multiple Familial Trichoepitheliomas: A Recurrent Association. ( 29972217 )
2018
33
[Morphology of non cutaneous head and neck squamous cell carcinoma]. ( 29209797 )
2018
34
Human Papilloma Virus 16/18: Fabricator of Trouble in Oral Squamous Cell Carcinoma. ( 29432879 )
2018
35
Obovatol inhibits the growth and aggressiveness of tongue squamous cell carcinoma through regulation of the EGFa89mediated JAKa89STAT signaling pathway. ( 29845251 )
2018
36
Proliferative Index in Invasive Tumor Front of Oral Squamous Cell Carcinoma: A Potential Prognostic Indicator. ( 29422466 )
2018
37
IGF2BP1 over-expression in skin squamous cell carcinoma cells is essential for cell growth. ( 29753746 )
2018
38
Prognostic Significance of Human Papilloma Virus and p16 Expression in Patients with Vulvar Squamous Cell Carcinoma who Received Radiotherapy. ( 29449057 )
2018
39
CD47 as a potential prognostic marker for oral leukoplakia and oral squamous cell carcinoma. ( 29805639 )
2018
40
Generation of highly differentiated BHY oral squamous cell carcinoma multicellular spheroids. ( 29435298 )
2018
41
Clinical value of miR-198-5p in lung squamous cell carcinoma assessed using microarray and RT-qPCR. ( 29394946 )
2018
42
Assessing the performance of a Loop Mediated Isothermal Amplification (LAMP) assay for the detection and subtyping of high-risk suptypes of Human Papilloma Virus (HPV) for Oropharyngeal Squamous Cell Carcinoma (OPSCC) without DNA purification. ( 29422018 )
2018
43
Distinguishing Anal Squamous Cell Carcinoma and Rectal Squamous Cell Carcinoma in Secondary Data Sets. ( 29420432 )
2018
44
Esophageal carcinosarcoma comprised of minimally invasive squamous cell carcinoma and undifferentiated pleomorphic sarcoma: A collision cancer? ( 29934989 )
2018
45
Unusual Papillary Squamous Cell Carcinoma of the Tip of Tongue Presenting in a Patient Status Post Heart Transplant. ( 29970551 )
2018
46
Oral squamous cell carcinoma profile in North-Eastern regions of India from habits to histopathology: A hospital-based study. ( 29937660 )
2018
47
ZNF750 Expression Is a Potential Prognostic Biomarker in Esophageal Squamous Cell Carcinoma. ( 29216641 )
2018
48
Pretreatment Lymphocyte to Monocyte Ratio as a Prognostic Marker for Advanced Pulmonary Squamous Cell Carcinoma Treated With Chemotherapy. ( 29977424 )
2018
49
Prognostic value of tumor volume in patients with head and neck squamous cell carcinoma treated with primary surgery. ( 29272056 )
2018
50
LINC00511 interacts with miR-765 and modulates tongue squamous cell carcinoma progression by targeting LAMC2. ( 29315846 )
2018

Variations for Squamous Cell Carcinoma

ClinVar genetic disease variations for Squamous Cell Carcinoma:

6
(show top 50) (show all 216)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
2 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
3 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
4 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
5 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh37 Chromosome 17, 7577124: 7577124
6 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh38 Chromosome 17, 7673806: 7673806
7 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
8 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
9 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Pathogenic rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
10 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
11 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
12 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
13 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
14 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
15 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
16 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
17 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
18 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
19 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403
20 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic rs121913357 GRCh38 Chromosome 7, 140781603: 140781603
21 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
22 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic rs121913355 GRCh38 Chromosome 7, 140781602: 140781602
23 BRAF NM_004333.4(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
24 BRAF NM_004333.4(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic rs121913355 GRCh38 Chromosome 7, 140781602: 140781602
25 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
26 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
27 BRAF NM_004333.4(BRAF): c.1406G> T (p.Gly469Val) single nucleotide variant Pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
28 BRAF NM_004333.4(BRAF): c.1406G> T (p.Gly469Val) single nucleotide variant Pathogenic rs121913355 GRCh38 Chromosome 7, 140781602: 140781602
29 STK19 NM_004197.1(STK19): c.265G> A (p.Asp89Asn) single nucleotide variant Likely pathogenic rs267600971 GRCh37 Chromosome 6, 31940123: 31940123
30 STK19 NM_004197.1(STK19): c.265G> A (p.Asp89Asn) single nucleotide variant Likely pathogenic rs267600971 GRCh38 Chromosome 6, 31972346: 31972346
31 STK19 NM_004197.1(STK19): c.265G> A (p.Asp89Asn) single nucleotide variant Likely pathogenic rs267600971 NCBI36 Chromosome 6, 32048102: 32048102
32 CDKN2A NM_000077.4(CDKN2A): c.341C> T (p.Pro114Leu) single nucleotide variant Likely pathogenic rs121913386 GRCh37 Chromosome 9, 21971017: 21971017
33 CDKN2A NM_000077.4(CDKN2A): c.341C> T (p.Pro114Leu) single nucleotide variant Likely pathogenic rs121913386 GRCh38 Chromosome 9, 21971018: 21971018
34 CDKN2A NM_000077.4(CDKN2A): c.341C> T (p.Pro114Leu) single nucleotide variant Likely pathogenic rs121913386 NCBI36 Chromosome 9, 21961017: 21961017
35 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
36 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic rs587780070 GRCh38 Chromosome 17, 7675077: 7675077
37 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
38 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
39 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
40 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
41 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
42 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
43 TP53 NM_000546.5(TP53): c.706T> G (p.Tyr236Asp) single nucleotide variant Pathogenic rs587782289 GRCh37 Chromosome 17, 7577575: 7577575
44 TP53 NM_000546.5(TP53): c.706T> G (p.Tyr236Asp) single nucleotide variant Pathogenic rs587782289 GRCh38 Chromosome 17, 7674257: 7674257
45 TP53 NM_001126115.1(TP53): c.443G> T (p.Arg148Ile) single nucleotide variant Uncertain significance rs121912660 GRCh38 Chromosome 17, 7673781: 7673781
46 TP53 NM_001126115.1(TP53): c.443G> T (p.Arg148Ile) single nucleotide variant Uncertain significance rs121912660 GRCh37 Chromosome 17, 7577099: 7577099
47 TP53 NM_001126115.1(TP53): c.401G> A (p.Gly134Glu) single nucleotide variant Conflicting interpretations of pathogenicity rs193920774 GRCh38 Chromosome 17, 7673823: 7673823
48 TP53 NM_001126115.1(TP53): c.401G> A (p.Gly134Glu) single nucleotide variant Conflicting interpretations of pathogenicity rs193920774 GRCh37 Chromosome 17, 7577141: 7577141
49 TP53 NM_000546.5(TP53): c.722C> G (p.Ser241Cys) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
50 TP53 NM_000546.5(TP53): c.722C> G (p.Ser241Cys) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241

Cosmic variations for Squamous Cell Carcinoma:

9
(show top 50) (show all 1933)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM43751 TP53 skin,hand,carcinoma,squamous cell carcinoma c.673-1G>A p.? 17:7674291-7674291 33
2 COSM10988 TP53 skin,face,carcinoma,squamous cell carcinoma c.772G>A p.E258K 17:7674191-7674191 33
3 COSM10705 TP53 skin,face,carcinoma,squamous cell carcinoma c.586C>T p.R196* 17:7674945-7674945 33
4 COSM44225 TP53 skin,arm,carcinoma,squamous cell carcinoma c.859G>A p.E287K 17:7673761-7673761 33
5 COSM10701 TP53 skin,ear,carcinoma,squamous cell carcinoma c.824G>T p.C275F 17:7673796-7673796 33
6 COSM43544 TP53 skin,face,carcinoma,squamous cell carcinoma c.260C>A p.P87Q 17:7676109-7676109 33
7 COSM10656 TP53 skin,arm,carcinoma,squamous cell carcinoma c.742C>T p.R248W 17:7674221-7674221 33
8 COSM44326 TP53 skin,face,carcinoma,squamous cell carcinoma c.706T>C p.Y236H 17:7674257-7674257 33
9 COSM6903965 TP53 skin,ear,carcinoma,squamous cell carcinoma c.988C>T p.L330F 17:7673540-7673540 33
10 COSM45114 TP53 skin,ear,carcinoma,squamous cell carcinoma c.702C>A p.Y234* 17:7674261-7674261 33
11 COSM44832 TP53 skin,arm,carcinoma,squamous cell carcinoma c.1096T>G p.S366A 17:7670613-7670613 33
12 COSM45830 TP53 skin,face,carcinoma,squamous cell carcinoma c.766A>C p.T256P 17:7674197-7674197 33
13 COSM45304 TP53 skin,face,carcinoma,squamous cell carcinoma c.375+1G>A p.? 17:7675993-7675993 33
14 COSM10788 TP53 skin,ear,carcinoma,squamous cell carcinoma c.764T>G p.I255S 17:7674199-7674199 33
15 COSM43588 TP53 skin,face,carcinoma,squamous cell carcinoma c.740A>C p.N247T 17:7674223-7674223 33
16 COSM10886 TP53 skin,hand,carcinoma,squamous cell carcinoma c.310C>T p.Q104* 17:7676059-7676059 33
17 COSM11081 TP53 skin,face,carcinoma,squamous cell carcinoma c.733G>T p.G245C 17:7674230-7674230 33
18 COSM10733 TP53 skin,face,carcinoma,squamous cell carcinoma c.574C>T p.Q192* 17:7674957-7674957 33
19 COSM10794 TP53 skin,ear,carcinoma,squamous cell carcinoma c.796G>A p.G266R 17:7673824-7673824 33
20 COSM43651 TP53 skin,face,carcinoma,squamous cell carcinoma c.763A>T p.I255F 17:7674200-7674200 33
21 COSM43753 TP53 skin,hand,carcinoma,squamous cell carcinoma c.560-1G>A p.? 17:7674972-7674972 33
22 COSM43537 TP53 skin,hand,carcinoma,squamous cell carcinoma c.565G>A p.A189T 17:7674966-7674966 33
23 COSM10660 TP53 skin,hand,carcinoma,squamous cell carcinoma c.818G>A p.R273H 17:7673802-7673802 33
24 COSM44923 TP53 skin,hand,carcinoma,squamous cell carcinoma c.565G>C p.A189P 17:7674966-7674966 33
25 COSM43665 TP53 skin,face,carcinoma,squamous cell carcinoma c.746G>C p.R249T 17:7674217-7674217 33
26 COSM46278 TP53 skin,hand,carcinoma,squamous cell carcinoma c.950A>G p.Q317R 17:7673578-7673578 33
27 COSM45145 TP53 skin,hand,carcinoma,squamous cell carcinoma c.590T>C p.V197A 17:7674941-7674941 33
28 COSM44274 TP53 skin,hand,carcinoma,squamous cell carcinoma c.647T>A p.V216E 17:7674884-7674884 33
29 COSM45677 TP53 skin,face,carcinoma,squamous cell carcinoma c.714T>A p.C238* 17:7674249-7674249 33
30 COSM44306 TP53 skin,hand,carcinoma,squamous cell carcinoma c.845G>C p.R282P 17:7673775-7673775 33
31 COSM607136 TGFBR1 skin,neck,carcinoma,squamous cell carcinoma c.1247C>T p.S416F 9:99146601-99146601 33
32 COSM6962965 SMO skin,neck,carcinoma,squamous cell carcinoma c.1103C>T p.P368L 7:129206332-129206332 33
33 COSM6933705 RPTOR skin,ear,carcinoma,squamous cell carcinoma c.8C>A p.S3Y 17:80545637-80545637 33
34 COSM6962990 RARA skin,neck,carcinoma,squamous cell carcinoma c.1384C>T p.P462S 17:40356221-40356221 33
35 COSM6962984 RAD52 skin,neck,carcinoma,squamous cell carcinoma c.439G>A p.V147M 12:927173-927173 33
36 COSM6962994 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 33
37 COSM6962992 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 33
38 COSM6933707 PTPRS skin,ear,carcinoma,squamous cell carcinoma c.5600A>C p.K1867T 19:5208279-5208279 33
39 COSM6962970 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.1736G>A p.S579N 9:8504347-8504347 33
40 COSM456125 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.5048C>T p.S1683F 9:8341168-8341168 33
41 COSM1700914 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.1261C>T p.P421S 9:8518130-8518130 33
42 COSM17489 PTCH1 skin,face,carcinoma,squamous cell carcinoma c.3724G>A p.E1242K 9:95449149-95449149 33
43 COSM6962989 PLCG2 skin,neck,carcinoma,squamous cell carcinoma c.115G>T p.E39* 16:81786104-81786104 33
44 COSM6962963 PIK3CG skin,neck,carcinoma,squamous cell carcinoma c.310G>A p.G104R 7:106867871-106867871 33
45 COSM6962964 PIK3CG skin,neck,carcinoma,squamous cell carcinoma c.3227G>A p.R1076K 7:106905305-106905305 33
46 COSM564 NRAS skin,neck,carcinoma,squamous cell carcinoma c.35G>A p.G12D 1:114716126-114716126 33
47 COSM585 NRAS skin,face,carcinoma,squamous cell carcinoma c.183A>T p.Q61H 1:114713907-114713907 33
48 COSM6903909 NRAS skin,face,carcinoma,squamous cell carcinoma c.443C>T p.T148I 1:114709576-114709576 33
49 COSM574 NRAS skin,face,carcinoma,squamous cell carcinoma c.38G>T p.G13V 1:114716123-114716123 33
50 COSM6903910 NRAS skin,hand,carcinoma,squamous cell carcinoma c.395A>G p.E132G 1:114709624-114709624 33

Copy number variations for Squamous Cell Carcinoma from CNVD:

7 (show top 50) (show all 98)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13821 1 1 7200000 Copy number TP73 Squamous cell cancer
2 25151 1 184907591 184916179 Amplification PTGS2 Squamous cell cancer
3 31938 1 32200000 39600000 Copy number Squamous cell cancer
4 33706 1 47467454 47552406 Amplification STIL Squamous cell cancer
5 42802 10 40300000 135374737 Copy number Squamous cell cancer
6 49690 11 110000000 134452384 Copy number Squamous cell cancer
7 49993 11 112500000 114500000 Copy number IGSF4 Squamous cell cancer
8 57469 11 63400000 77100000 Copy number GSTP1 Squamous cell cancer
9 57471 11 63400000 77100000 Copy number MEN1 Squamous cell cancer
10 61508 12 1 3100000 Gain LOC440123 Squamous cell cancer
11 61509 12 1 3100000 Gain SLC6A12 Squamous cell cancer
12 61511 12 1 3100000 Gain SLC6A13 Squamous cell cancer
13 61529 12 1 35400000 Copy number Squamous cell cancer
14 61608 12 10000000 12600000 Gain CDKN1B Squamous cell cancer
15 61609 12 10000000 12600000 Gain DKFZP434F0318 Squamous cell cancer
16 66096 12 25249446 25295130 Amplification KRAS Squamous cell cancer
17 66577 12 3100000 5300000 Gain LOC399986 Squamous cell cancer
18 66579 12 3100000 5300000 Gain LOC441627 Squamous cell cancer
19 66581 12 3100000 5300000 Gain TSPAN9 Squamous cell cancer
20 75264 13 18400000 72100000 Copy number Squamous cell cancer
21 77032 13 39500000 46200000 Copy number Squamous cell cancer
22 87575 14 74815283 74818665 Amplification FOS Squamous cell cancer
23 93656 15 57100000 61500000 Loss RORA Squamous cell cancer
24 95697 15 79500000 83000000 Loss DNM1DN11-6 Squamous cell cancer
25 95699 15 79500000 83000000 Loss LOC159170 Squamous cell cancer
26 95701 15 79500000 83000000 Loss LOC161527 Squamous cell cancer
27 95703 15 79500000 83000000 Loss LOC388152 Squamous cell cancer
28 95705 15 79500000 83000000 Loss LOC388160 Squamous cell cancer
29 95707 15 79500000 83000000 Loss LOC440300 Squamous cell cancer
30 95709 15 79500000 83000000 Loss LOC440301 Squamous cell cancer
31 97922 16 14700000 16700000 Loss Squamous cell cancer
32 107539 17 15900000 22100000 Loss Squamous cell cancer
33 111141 17 35097918 35138441 Amplification ERBB2 Squamous cell cancer
34 116535 17 6800000 11200000 Copy number Squamous cell cancer
35 122734 18 59800000 76117153 Copy number Squamous cell cancer
36 123838 18 89115825 89123587 Amplification SPP1 Squamous cell cancer
37 124166 19 1 6900000 Gain BSG Squamous cell cancer
38 124167 19 1 6900000 Gain C19orf19 Squamous cell cancer
39 124168 19 1 6900000 Gain C19orf20 Squamous cell cancer
40 124170 19 1 6900000 Gain CDC34 Squamous cell cancer
41 124171 19 1 6900000 Gain GZMM Squamous cell cancer
42 124173 19 1 6900000 Gain MADCAM1 Squamous cell cancer
43 124175 19 1 6900000 Gain SCHC2 Squamous cell cancer
44 135627 2 118600000 122100000 Gain Squamous cell cancer
45 166091 3 1 3500000 Loss APOD Squamous cell cancer
46 166092 3 1 3500000 Loss CCR2 Squamous cell cancer
47 166093 3 1 3500000 Loss CCRL2 Squamous cell cancer
48 169828 3 14700000 30800000 Copy number Squamous cell cancer
49 171547 3 169200000 172500000 Gain EVI1 Squamous cell cancer
50 171549 3 169200000 172500000 Gain LOC389174 Squamous cell cancer

Expression for Squamous Cell Carcinoma

Search GEO for disease gene expression data for Squamous Cell Carcinoma.

Pathways for Squamous Cell Carcinoma

Pathways related to Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.48 BRAF HRAS TP53
2 11.36 BRAF HRAS TP53
3 11 BRAF HRAS TP53
4 9.88 HOTAIR TP53 UCA1

GO Terms for Squamous Cell Carcinoma

Sources for Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....